The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Nine months.
In March 2020, the United States was in the early stages of the COVID-19 pandemic. We shut the entire country down and ground the economy to a halt in an effort to slow the spread of the virus. Think back to March, and how much uncertainty we were living under.
Nine months later, the FDA approved two COVID-19 vaccines under emergency authorization. Before New Year’s Day, millions of Americans had received the vaccine, including front-line physicians and health care providers and nursing home patients, our most vulnerable citizens.
Nine months. Take a moment to let that sink in.
The mainstream media has crafted a narrative around the COVID-19 pandemic that’s almost entirely negative. For the purpose of ratings, they have described the U.S. response to the pandemic as blundering from one mistake to the next. This narrative is false.
There is another way — a more accurate and underappreciated way — to tell the story of the last nine months. It is a story of heroism, innovation, and precise science, performed under unbelievable pressure.
Let’s not mince words: The United States and the world needs to appreciate the role of the pharmaceutical industry — the researchers, physicians and business leaders — who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.
Instead of dwelling on why many in the media are ignoring this, let’s review some facts.
The next step of the process — distribution of the vaccine — will be as challenging as the development phase, if not more so. But again, the pharmaceutical industry is rising to the occasion. Factories around the world are working in overdrive to produce hundreds of millions of vaccine doses.
Already, less than a month after the Pfizer vaccine was approved, more than 15.4 million doses of vaccine have been distributed across the country, and more than 4.6 million people have received their first dose, according to CDC data. Many patients are already receiving their second dose.
While 15.4 million doses are impressive, some expected 20 million doses. But even that is moving the goal line a bit, as six months ago many observers didn’t think we’d get a vaccine until 2021.
Members of our COVID Coalition told us that the holidays slowed the rollout considerably. Nancy Messonnier, M.D., a physician with the National Center for Immunization and Respiratory Diseases at the CDC, expects a rapid jump in administered vaccines during these first few days of 2021.
Every day, more people will be vaccinated. After health care workers and our most vulnerable citizens, other frontline workers will be next. Teachers will be vaccinated so our children can return to school. And soon, all Americans will be able to go to their doctor or walk into a CVS or Walgreens and receive the vaccine.
Remember, we did all this in nine months, with the help, dedication and expertise of our pharmaceutical industry heroes. Next time you turn on the TV and see negativity, turn it off and imagine instead where we will be nine months from now.
Mike Hennessy Sr is the founder and chairman of MJH Life Sciences.
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.